These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33565344)

  • 21. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein-associated phospholipase A₂ activity is increased in patients with definite familial hypercholesterolemia compared with other forms of hypercholesterolemia.
    Mattina A; Rosenbaum D; Bittar R; Bonnefont-Rousselot D; Noto D; Averna M; Bruckert E; Giral P
    Nutr Metab Cardiovasc Dis; 2018 May; 28(5):517-523. PubMed ID: 29525223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters.
    Vuorio A; Kovanen PT
    Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein(a) as Part of the Diagnosis of Clinical Familial Hypercholesterolemia.
    Langsted A; Nordestgaard BG
    Curr Atheroscler Rep; 2022 Apr; 24(4):289-296. PubMed ID: 35107760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and characterization of severe familial hypercholesterolemia in patients presenting for cardiac catheterization.
    Zafrir B; Shapira C; Lavie G; Halon DA; Flugelman MY
    J Clin Lipidol; 2016; 10(6):1338-1343. PubMed ID: 27919350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers.
    Besseling J; Kindt I; Hof M; Kastelein JJ; Hutten BA; Hovingh GK
    Atherosclerosis; 2014 Mar; 233(1):219-23. PubMed ID: 24529147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review.
    Narverud I; Retterstøl K; Iversen PO; Halvorsen B; Ueland T; Ulven SM; Ose L; Aukrust P; Veierød MB; Holven KB
    Atherosclerosis; 2014 Aug; 235(2):299-309. PubMed ID: 24908240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C.
    van Delden XM; Huijgen R; Wolmarans KH; Brice BC; Barron JK; Blom DJ; Marais AD
    Atherosclerosis; 2018 Oct; 277():327-333. PubMed ID: 30270067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease.
    Trinder M; Francis GA; Brunham LR
    JAMA Cardiol; 2020 Apr; 5(4):390-399. PubMed ID: 32049305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
    D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
    J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the care of familial hypercholesterolaemia: 2016.
    Bell DA; Watts GF
    Med J Aust; 2016 Sep; 205(5):232-6. PubMed ID: 27581271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Risk Misperception and Low Awareness of Familial Hypercholesterolemia in Individuals with Severe Hypercholesterolemia.
    Santos RD; Pereira C; Cesena F; Laurinavicius AG; Tabone V; Bittencourt MS
    Arq Bras Cardiol; 2021 Mar; 116(4):706-712. PubMed ID: 33566934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polygenic Contribution to Low-Density Lipoprotein Cholesterol Levels and Cardiovascular Risk in Monogenic Familial Hypercholesterolemia.
    Trinder M; Paquette M; Cermakova L; Ban MR; Hegele RA; Baass A; Brunham LR
    Circ Genom Precis Med; 2020 Oct; 13(5):515-523. PubMed ID: 33079599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Features and Gaps in the Management of Probable Familial Hypercholesterolemia and Cardiovascular Disease.
    Zafrir B; Jubran A; Lavie G; Halon DA; Flugelman MY; Shapira C
    Circ J; 2017 Dec; 82(1):218-223. PubMed ID: 28701632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography.
    Lee WJ; Chuang HN; Chen YM; Liang KW; Tung H; Chen JP; Lee IT; Wang JS; Lin CH; Lin HJ; Sheu WH; Lee WL; Hsiao TH
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
    Brandts J; Ray KK
    Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.
    Homma K; Homma Y; Yoshida T; Ozawa H; Shiina Y; Wakino S; Hayashi K; Itoh H; Hori S
    J Clin Lipidol; 2015; 9(2):210-6. PubMed ID: 25911077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of heterozygous familial hypercholesterolemia: what does the future hold?
    Polychronopoulos G; Tziomalos K
    Expert Rev Clin Pharmacol; 2020 Nov; 13(11):1229-1234. PubMed ID: 33070644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.